UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018913
Receipt number R000021882
Scientific Title Effects of SGLT-2 inhibitors for the patients with non-alcoholic fatty liver disease (NAFLD) complicated with type 2 diabetes mellitus.
Date of disclosure of the study information 2015/09/04
Last modified on 2020/09/09 19:36:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of SGLT-2 inhibitors for the patients with non-alcoholic fatty liver disease (NAFLD) complicated with type 2 diabetes mellitus.

Acronym

SGLT-2 and NAFLD/T2DM

Scientific Title

Effects of SGLT-2 inhibitors for the patients with non-alcoholic fatty liver disease (NAFLD) complicated with type 2 diabetes mellitus.

Scientific Title:Acronym

SGLT-2 and NAFLD/T2DM

Region

Japan


Condition

Condition

Non-alcoholic fatty liver disease (NAFLD) complicated with type 2 diabetes mellitus.

Classification by specialty

Medicine in general Hepato-biliary-pancreatic medicine Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effect of SGLT-2 inhibitors for the patients with non-alcoholic fatty liver disease (NAFLD) complicated with type 2 diabetes mellitus.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase IV


Assessment

Primary outcomes

GGT

Key secondary outcomes

HbA1c, Body weight, HOMA-IR


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Uncontrolled Type 2 DM patients after 3 months of diet/exercise therapy
2) Diagnosed as fatty liver
3) BMI >/= 25kg/m2
4) GGT >/= 1.5 x normal limits
5) Need for SGLT-2 inhibitors administration
6) HbA1c >/= 6.5%

Key exclusion criteria

1) History of allergy to SGLT-2 inhibitors
2) HB/HC/autoimmune hepatitis
3) Pregnancy or lactation in women
4) Under insulin treatment
5) Excess alcohol consumption
male; >/= 30g/day
female; >/= 20g/day
6) Inadequacy for this therapy

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Satoru
Middle name
Last name Kakizaki

Organization

Gunma University Graduate School of Medicine

Division name

Department of Medicine and Molecular Science

Zip code

3718511

Address

3-39-15 Showa-machi, Maebashi, Gunma, Japan

TEL

027-220-8127

Email

kakizaki@gunma-u.ac.jp


Public contact

Name of contact person

1st name Satoru
Middle name
Last name Kakizaki

Organization

Gunma University Graduate School of Medicine

Division name

Department of Medicine and Molecular Science

Zip code

3718511

Address

3-39-15 Showa-machi, Maebashi, Gunma, Japan

TEL

027-220-8127

Homepage URL


Email

kakizaki@gunma-u.ac.jp


Sponsor or person

Institute

Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Affiliated Hospitals to Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Department of Clinical Research, Gunma University

Address

3-39-15 Showa-machi, Maebashi, Gunma, Japan

Tel

027-220-8740

Email

gunmaciru-office@umin.ac.jp


Secondary IDs

Secondary IDs

YES

Study ID_1

1348

Org. issuing International ID_1

Gunma University Hospital

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

群馬大学附属病院


Other administrative information

Date of disclosure of the study information

2015 Year 09 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2015 Year 09 Month 02 Day

Date of IRB


Anticipated trial start date

2015 Year 10 Month 01 Day

Last follow-up date

2016 Year 10 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Cohort Study
Recruitment of Subject
From October/2015 to March/2016,
The patients meet the inclusion/exclusion criteria.


Management information

Registered date

2015 Year 09 Month 04 Day

Last modified on

2020 Year 09 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021882


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name